Pre-exposure prophylaxis (PrEP) is the term used to refer to HIV-negative people taking antiretroviral (ARV) drugs on an ongoing basis to reduce the risk of acquiring HIV.
The ARV drug Truvada has been demonstrated to be effective in clinical trials among men who have sex with men (MSM), transgender women, heterosexual men and women, and injecting drug users.
In 2012, the US regulatory authority approved the drug Truvada for use as PrEP.
Truvada was approved for use as PrEP in Australia on 6 May 2016, although it has yet to be added to the Pharmaceutical Benefits Scheme (PBS) listing, so it is still too expensive for individuals to purchase it in Australia.
Since mid-2014, Truvada PrEP has been available in a limited way through demonstration projects in some states.
These projects, which have expanded their recruitment in 2016, are investigating the acceptability, feasibility and impact of providing Truvada for HIV prevention on an ongoing basis.
AFAO advocates for PrEP to be subsidised on the PBS so that more people can access the drug outside of demonstration projects.
AFAO also recommends that ongoing access to Truvada is ensured for participants at the conclusion of these studies.
AFAO welcomes approval of Truvada for PrEP (May 2016)
AFAO Briefing Paper on PrEP (2015 - PDF)
Participate in a trial:
EPIC-NSW (Expanded PrEP Implementation in Communities in NSW) will began recruiting in late February 2016. The trial has places for 3,700 people at high risk of HIV.
QPrEP, a joint initiative of the Department of Health, Queensland AIDS Council, and the HIV Foundation Queensland, launched August 2015. Details of an expanded roll-out (announced April 2016) are currently being finalised, which will see PrEP offered to up to 2,000 men at risk of HIV in Queensland. Contact QuAC to register interest in participating.
PrEPX is the result of a partnership between the Victorian Government, Alfred Health, the Burnet Institute and the Victorian AIDS Council (VAC). The trial is anticipated to commence by mid-2016, and will offer PrEP to 2,600 people in Victoria. The trial superseded the VicPrEP trial (see below).
VicPrEP based in Victoria, explores the acceptability, safety, impact and feasibility of prescribing PrEP to people at risk of HIV infection. The VicPrEP study will continue until June 2017. All VicPrEP participants have a spot reserved for them in PrEPX and will be transitioned to that study on completing VicPrEP.
AVAC clearing house of information about PrEP, including trials taking place around the world.
Ending HIV, includes info about accessing PrEP in NSW and links to other PrEP resources.
#ComePrEPd, Queensland AIDS Council's community driven PrEP awareness campaign.
This page was published on 12 January, 2011
This page was reviewed on 10 May 2016
All content contained within this website is copyright © AFAO, unless otherwise stated. Content may be reproduced for non-commercial, personal research or educational purposes free of charge, provided the following citation is made: "Reprinted from [name of publication], published by the Australian Federation of AIDS Organisations". Contact AFAO regarding other uses of content.